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Sir,
We are honoured with the opportunity to reply on the comment of
Jacobs et al and on the comment of Mourits et al.
Firstly, Jacobs et al, who are experts in the field of surveillance of the
ovaries, conclude that there remains a need for screening in younger
women, who want to preserve fertility or avoid premature menopause for
the following reasons: (1) lack of reliable data on annual surveillance in
high-risk women (Hogg and Friedlander, 2004), (2) the underpowerment of
our study on surveillance in high-risk women (Oei et al, 2006) and (3) Hogg
and Friedlander (2004) suggested that annual screening does not have
adequate sensitivity to detect early stage disease.
Above-mentioned comments may be true. On the other hand, especially
in young women the number of women needed to screen to identify one
patient with ovarian cancer will be extremely high, owing to the relatively
low risk to develop ovarian cancer under the age of 40 (Antoniou et al,
2005). Moreover, this will lead to a higher number of additional
interventions (diagnostic laparoscopies) owing to false-positive abnormal-
ities in premenopausal women. Additional studies, mentioned in our
publication, were not capable to detect all ovarian cancers nor ovarian
cancer at an early stage disease in this group of high-risk women
(Meeuwissen et al, 2005; Stirling et al, 2005; Vasen et al, 2005). In the study,
population of Jacobs et al approximately 40% is above the age of 50 years.
In our study the majority of the patients aged 50 years or up, underwent
bilateral salpingo-oophorectomy (BSO).
We do agree with Jacobs et al that further research on early detection
methods for ovarian cancer in this group of women should be undertaken.
Hopefully, new methods can broaden the range of effective possibilities
in the management of these high-risk women. We look forward to the
results of the UK Familial Ovarian Cancer Screening Study (UKFOCSS) and
the Cancer Genetics Network (CGN) CA125 studies initiated in the UK.
Secondly, we agree with Mourits et al that the presence of monolocular
cysts should have been part of the method section especially because the
majority of abnormalities at TVU were caused by these kind of cysts. In
future studies these monolocular cysts should be identified and registered as
a separate category. Regarding the issue on loss of quality of life in women
with false-positive TVU findings as addressed by Mourits et al, our study is
not capable to answer this question. Although we agree that quality of life is
an important issue, our study was not designed to address this point.
In conclusion, until the results of earlier mentioned studies are available,
we consider BSO the only evidence-based risk-reducing method for women
at high risk of ovarian cancer (Kauff et al, 2002). Moreover, BSO also reduces
the risk of breast cancer in premenopausal BRCA mutation carriers (Kauff
et al, 2002). Short-term use of hormone replacement therapy after BSO have
already been proven to be safe (Rebbeck et al, 2005) whereas Madalinska
et al, (2005) showed that after BSO women experience fewer breast and
ovarian cancer worries, and have a more favourable cancer risk perception.
We feel obliged to counsel high-risk women for BSO from age 35–40 by
emphasising the advantages of BSO and the limitations of surveillance.
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